Axillary lymph node count is lower after neoadjuvant chemotherapy

Am J Surg. 2006 Jun;191(6):827-9. doi: 10.1016/j.amjsurg.2005.08.041.

Abstract

Background: Retrieval of fewer than 10 lymph nodes at axillary dissection (ALND) for breast cancer can represent anatomic variation or inadequate dissection. We postulated that despite aggressive ALND, a lower lymph node count is more frequent after neoadjuvant chemotherapy.

Methods: Patients who received neoadjuvant chemotherapy followed by ALND were compared with patients who received surgery first. All patients received a level I and II ALND at a single institution by one of the breast surgeons. The number of nodes retrieved at ALND was dichotomized into categories (< 10 and > or = 10), and compared using Fisher exact test.

Results: A total of 143 neoadjuvant and 170 surgery-first patients were studied. Patients treated with neoadjuvant chemotherapy were significantly more likely to have fewer than 10 lymph nodes retrieved at ALND than were the surgery-first patients (19/143 or 13% vs. 6/170 or 4%, P = .003).

Conclusions: A low lymph node count is more common in patients after treatment with neoadjuvant chemotherapy and should not be assumed to represent an incomplete ALND.

Publication types

  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Axilla
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / surgery
  • Female
  • Humans
  • Lymph Node Excision / methods
  • Lymph Nodes / pathology*
  • Lymph Nodes / surgery
  • Lymphatic Metastasis / pathology
  • Lymphatic Metastasis / prevention & control
  • Mastectomy / methods
  • Middle Aged
  • Neoadjuvant Therapy*
  • Neoplasm Invasiveness / pathology*
  • Neoplasm Staging
  • Probability
  • Prognosis
  • Prospective Studies
  • Sentinel Lymph Node Biopsy
  • Statistics, Nonparametric
  • Treatment Outcome

Substances

  • Antineoplastic Agents